R&D channel feed – Endpoints News

R&D channel feed

Semma steps toward the clinic after demonstrating effect of potential diabetes cure in landmark animal studies

6 years ago

Scoring Pfizer v Sarepta: This round on Duchenne gene therapy goes to the little biotech, but the pharma Goliath has plenty of punch left

6 years ago

Unfazed by failure, PTC Therapeutics to appeal negative EMA decision on its disaster prone Duchenne drug

6 years ago

Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal

6 years ago

Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors

6 years ago

Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike

6 years ago

Turned back at the FDA, ImmunoGen is axing 220 staffers, selling programs and hunkering down for a new PhIII gamble

6 years ago

Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads

6 years ago

AstraZeneca challenges Roche on frontline SCLC after seizing an interim win — and Merck may not be far behind

6 years ago

Two biotech unicorns swell proposed IPOs, eyeing a $600M-plus windfall

6 years ago

Novartis holds back the copycat brigade's attack on its top drug franchise — for now

6 years ago

Arch-backed ImmusanT scraps PhII as celiac therapy flops in a key test

6 years ago

FDA rejects Acer's rare disease drug, asks for new trial — shares crater

6 years ago

Aldeyra's eye drug fails pivotal test in patients with rare, inflammatory disease

6 years ago

Suffering Novartis partner Conatus grabs the ax and packs it in on NASH after a series of setbacks

6 years ago

Better than Ambien? Minerva soars on PhIIb update on seltorexant for insomnia

6 years ago

Gene therapy biotech sees its stock rocket higher on promising results for rare cases of butterfly disease

6 years ago

AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud

6 years ago

Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market

6 years ago

Following news of job cuts in European R&D ops, Sanofi confirms it’s offering US workers an 'early exit'

6 years ago

Regeneron/Sanofi's antibody underwhelms in asthma study — shares of rival AnaptysBio pay the price

6 years ago

Green-lighted in Japan, FDA quickly spurns Daiichi Sankyo's flawed application for AML drug

6 years ago

HIV, pneumococcal — and what? Merck's unexpected pipeline highlight excites a little biotech

6 years ago

Roche/Exelixis' Cotellic fizzles in pivotal melanoma study

6 years ago

First page Previous page 240 241 242243244 245 246 Next page Last page